Skip to main content

Table 1 Treatment initiation and continuation regimens of Phase 3 randomized controlled trial of anti-VEGF in DME

From: Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data

Randomized controlled trial Initiation and continuation regimen Time to maximum mean BCVA*
RIDE/RISE
NCT00473382
NCT00473330
Fixed q4 intervals ranibizumab
 (no reduction before week 156 in the open-label extension) [4]
Week 88/week 92
RESTORE
NCT00687804
Initial 3 q4 intervals followed by PRN (protocol-driven) ranibizumab retreatment [5, 6] Week 40
RELIGHT
NCT01257815
Initial 3 q4 intervals followed by PRN (protocol-driven) ranibizumab retreatment [7] Week 24
REVEAL
NCT00989989
Initial 3 q4 intervals followed by PRN (protocol-driven) ranibizumab retreatment [8] Week 32
DRCR protocol I
NCT00445003
Initial 4 q4 intervals ranibizumab followed by protocol-driven ranibizumab retreatment [9] Week 232
DRCR.net protocol T
NCT01627249
Aggressive retreatment protocol for IAI, bevacizumab, and ranibizumab prior to 24-week visit with q4 intervals [10] Week 32, week 52
VIVID/VISTA
NCT01363440 NCT01331681
Initial 5 q4 intervals IAI followed by 2q8 or 2q4 intervals [11] Week 44
BOLT
EUDRACT2007-000847-89
Initial 3 q6 intervals bevacizumab (initially combined with laser) followed by PRN (protocol-driven) bevacizumab retreatment [12] Week 100
  1. q4, every 4 weeks
  2. * Within controlled/core study phase